KR101786843B1 - 지질 저하제를 포함하는 제제 - Google Patents

지질 저하제를 포함하는 제제 Download PDF

Info

Publication number
KR101786843B1
KR101786843B1 KR1020157036380A KR20157036380A KR101786843B1 KR 101786843 B1 KR101786843 B1 KR 101786843B1 KR 1020157036380 A KR1020157036380 A KR 1020157036380A KR 20157036380 A KR20157036380 A KR 20157036380A KR 101786843 B1 KR101786843 B1 KR 101786843B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
group
composition according
combination
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157036380A
Other languages
English (en)
Korean (ko)
Other versions
KR20160013150A (ko
Inventor
자이텐드레 디. 파텔
프라카쉬 다바드라
스네할 파텔
샤피끄 셰이크
Original Assignee
카딜라 핼쓰캐어 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카딜라 핼쓰캐어 리미티드 filed Critical 카딜라 핼쓰캐어 리미티드
Publication of KR20160013150A publication Critical patent/KR20160013150A/ko
Application granted granted Critical
Publication of KR101786843B1 publication Critical patent/KR101786843B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020157036380A 2013-07-25 2014-07-24 지질 저하제를 포함하는 제제 Expired - Fee Related KR101786843B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2470/MUM/2013 2013-07-25
IN2470MU2013 IN2013MU02470A (https=) 2013-07-25 2013-07-25
PCT/IN2014/000489 WO2015011730A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Publications (2)

Publication Number Publication Date
KR20160013150A KR20160013150A (ko) 2016-02-03
KR101786843B1 true KR101786843B1 (ko) 2017-10-18

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157036380A Expired - Fee Related KR101786843B1 (ko) 2013-07-25 2014-07-24 지질 저하제를 포함하는 제제

Country Status (22)

Country Link
US (2) US9610277B2 (https=)
EP (1) EP3024446A1 (https=)
JP (1) JP2016523895A (https=)
KR (1) KR101786843B1 (https=)
CN (1) CN105407873A (https=)
AP (1) AP2015008876A0 (https=)
AR (1) AR097067A1 (https=)
AU (1) AU2014294548B2 (https=)
BR (1) BR112015031878A2 (https=)
CA (1) CA2917923A1 (https=)
EA (1) EA201690072A1 (https=)
GE (1) GEP20186825B (https=)
HK (1) HK1219222A1 (https=)
IN (1) IN2013MU02470A (https=)
MA (1) MA38865A1 (https=)
MX (1) MX374628B (https=)
NZ (1) NZ714558A (https=)
PH (1) PH12015502802A1 (https=)
SG (1) SG11201509798PA (https=)
TW (1) TW201545773A (https=)
WO (1) WO2015011730A1 (https=)
ZA (1) ZA201508682B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022187B1 (en) 2006-05-23 2011-03-16 Intel Corporation Millimeter-wave communication system for an indoor area
KR101633720B1 (ko) 2011-01-31 2016-06-27 카딜라 핼쓰캐어 리미티드 지방이상증의 치료
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (https=) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (https=) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
MX382765B (es) 2016-12-09 2025-03-13 Zydus Lifesciences Ltd Tratamiento para la colangitis biliar primaria.
EP3923932A4 (en) * 2019-02-13 2022-11-16 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004277415A (ja) * 2003-02-26 2004-10-07 Takeda Chem Ind Ltd 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
WO2012104869A1 (en) * 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
CZ1095A3 (en) 1992-07-03 1995-10-18 Smithkline Beecham Plc Heterocyclic compounds, process of their preparation, their use for the preparation of a pharmaceutical preparation and the pharmaceutical composition containing thereof
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
BR9608040B1 (pt) 1995-04-28 2010-02-23 composto taxàide pentacÍclico.
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
ES2449194T3 (es) 2000-01-19 2014-03-18 Cadila Healthcare Limited Compuestos que tienen actividades hipolipidémica e hipocolesterolémica, procedimiento para su preparación y composiciones farmacéuticas que los contienen
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20070051626A1 (en) 2003-09-26 2007-03-08 Chiho Itou Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
JP5058150B2 (ja) * 2006-02-22 2012-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化医薬組成物
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
LT2641596T (lt) 2009-11-26 2018-08-10 Genfit 1,3-difenilprop-2-en-1-ono darinių panaudojimas kepenų sutrikimų gydymui
EP2627323A4 (en) * 2010-10-12 2014-03-12 Univ Johns Hopkins HUSTENSTILLENDE COMPOSITIONS WITH MEMANTINE
UA114360C2 (uk) * 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (https=) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (https=) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004277415A (ja) * 2003-02-26 2004-10-07 Takeda Chem Ind Ltd 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
WO2012104869A1 (en) * 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy

Also Published As

Publication number Publication date
JP2016523895A (ja) 2016-08-12
MX374628B (es) 2025-03-06
MA38865A1 (fr) 2017-12-29
US20170266158A1 (en) 2017-09-21
IN2013MU02470A (https=) 2015-06-26
AU2014294548B2 (en) 2017-08-10
MX2015016971A (es) 2016-04-25
BR112015031878A2 (pt) 2017-07-25
CA2917923A1 (en) 2015-01-29
CN105407873A (zh) 2016-03-16
PH12015502802A1 (en) 2016-03-14
US20160136131A1 (en) 2016-05-19
SG11201509798PA (en) 2016-02-26
US9610277B2 (en) 2017-04-04
HK1219222A1 (zh) 2017-03-31
EP3024446A1 (en) 2016-06-01
GEP20186825B (en) 2018-02-26
US10098868B2 (en) 2018-10-16
EA201690072A1 (ru) 2016-06-30
WO2015011730A1 (en) 2015-01-29
ZA201508682B (en) 2017-03-29
AR097067A1 (es) 2016-02-17
AP2015008876A0 (en) 2015-11-30
NZ714558A (en) 2017-02-24
KR20160013150A (ko) 2016-02-03
AU2014294548A1 (en) 2015-12-17
TW201545773A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
KR101786843B1 (ko) 지질 저하제를 포함하는 제제
US9603794B2 (en) Preparations of effervescent formulations comprising cephalosporin and uses thereof
US20090281136A1 (en) Prasugrel pharmaceutical formulations
EP2231121B1 (en) Pharmaceutical compositions
KR20150067153A (ko) 티카그렐러를 함유하는 고형의 경구용 약학 제제
ES2397558T3 (es) Composición farmacéutica que comprende aleglitazar
JP5465867B2 (ja) 安定なエグアレンナトリウム固形製剤
EP3184103A1 (en) Pharmaceutical composition comprising atorvastatin or a salt thereof
JP7355846B2 (ja) 固形製剤
EP1965773B1 (en) Oral formulation of anhydrous olanzapine form i
KR20240141090A (ko) 용출률이 개선된 닌테다닙을 포함하는 약제학적 조성물
AU2003201879B2 (en) Pharmaceutical composition comprising 2,2-Dichloro-12-(4-chlorophenyl)-dodecanoic acid
JPH10226644A (ja) 医薬組成物
OA17603A (en) Formulation comprising a hypolipidemic agent.
KR20200002486A (ko) 습식과립 조성물, 이를 함유하는 정제 및 정제의 제조 방법
EP4527378A1 (en) A film coated tablet of brivaracetam
EP4356903A1 (en) Microtablets comprising lansoprazole
WO2018216933A1 (ko) 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
KR20200013018A (ko) 폴라프레징크를 포함하는 습식과립 조성물 및 이를 이용한 정제의 제조 방법
HK1069772A (en) Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl) dodecanoic acid
KR20200002409A (ko) 폴라프레징크를 포함하는 습식과립 조성물 및 이를 이용한 정제의 제조 방법
KR20070104890A (ko) 수난용성 활성 물질의 속방출형 경구 제형
JP2006182687A (ja) カプセル製剤

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20201012

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20201012

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000